1
|
Tchalova K, Lydon JE, Atkinson L, Fleming AS, Kennedy J, Lecompte V, Meaney MJ, Moss E, O'Donnell KA, O'Donnell KJ, Silveira PP, Sokolowski MB, Steiner M, Bartz JA. Variation in the mu-opioid receptor gene (OPRM1) moderates the influence of maternal sensitivity on child attachment. Transl Psychiatry 2024; 14:181. [PMID: 38580654 PMCID: PMC10997775 DOI: 10.1038/s41398-024-02888-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 03/15/2024] [Accepted: 03/20/2024] [Indexed: 04/07/2024] Open
Abstract
The endogenous opioid system is thought to play an important role in mother-infant attachment. In infant rhesus macaques, variation in the μ-opioid receptor gene (OPRM1) is related to differences in attachment behavior that emerges following repeated separation from the mother; specifically, infants carrying at least one copy of the minor G allele of the OPRM1 C77G polymorphism show heightened and more persistent separation distress, as well as a pattern of increased contact-seeking behavior directed towards the mother during reunions (at the expense of affiliation with other group members). Research in adult humans has also linked the minor G allele of the analogous OPRM1 A118G polymorphism with greater interpersonal sensitivity. Adopting an interactionist approach, we examined whether OPRM1 A118G genotype and maternal (in)sensitivity are associated with child attachment style, predicting that children carrying the G allele may be more likely to develop an ambivalent attachment pattern in response to less sensitive maternal care. The sample consisted of 191 mothers participating with their children (n = 223) in the Maternal Adversity, Vulnerability and Neurodevelopment (MAVAN) project, a community-based, birth cohort study of Canadian mothers and their children assessed longitudinally across the child's development. Maternal sensitivity was coded from at-home mother-child interactions videotaped when the child was 18 months of age. Child attachment was assessed at 36 months using the Strange Situation paradigm. As predicted, G allele carriers, but not AA homozygotes, showed increasing odds of being classified as ambivalently attached with decreasing levels of maternal sensitivity. Paralleling earlier non-human animal research, this work provides support for the theory that endogenous opioids contribute to the expression of attachment behaviors in humans.
Collapse
Affiliation(s)
- K Tchalova
- Department of Psychology, McGill University, Montréal, QC, Canada
| | - J E Lydon
- Department of Psychology, McGill University, Montréal, QC, Canada
| | - L Atkinson
- Department of Psychology, Toronto Metropolitan University, Toronto, ON, Canada
| | - A S Fleming
- Department of Psychology, University of Toronto Mississauga, Toronto, ON, Canada
| | - J Kennedy
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - V Lecompte
- L'Université du Québec à Montréal, Montréal, QC, Canada
| | - M J Meaney
- Department of Psychology, McGill University, Montréal, QC, Canada
- Douglas Research Centre, Montréal, QC, Canada
- Singapore Institute for Clinical Sciences, A*STAR, Singapore, Singapore
| | - E Moss
- L'Université du Québec à Montréal, Montréal, QC, Canada
| | - K A O'Donnell
- Yale School of Medicine, Yale University, New Haven, CT, USA
| | - K J O'Donnell
- Department of Psychology, Simon Fraser University, Burnaby, BC, Canada
| | - P P Silveira
- Department of Psychiatry, McGill University, Montréal, QC, Canada
| | - M B Sokolowski
- Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, ON, Canada
| | - M Steiner
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - J A Bartz
- Department of Psychology, McGill University, Montréal, QC, Canada.
| |
Collapse
|
2
|
Rametov NM, Steiner M, Bizhanova NA, Abdel ZZ, Yessimseit DT, Abdeliyev BZ, Mussagalieva RS. Mapping Plague Risk Using Super Species Distribution Models and Forecasts for Rodents in the Zhambyl Region, Kazakhstan. Geohealth 2023; 7:e2023GH000853. [PMID: 37965638 PMCID: PMC10641984 DOI: 10.1029/2023gh000853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 10/21/2023] [Accepted: 10/24/2023] [Indexed: 11/16/2023]
Abstract
One of the most extensive natural plague centers, or foci, is located in Central Asia, in particular, the Zhambyl region in Southern Kazakhstan. Here, we conducted plague surveillance from 2000 to 2020 in the Zhambyl region in Kazakhstan and confirmed 3,072 cases of infected wild animals. We used Species Distribution Modeling by employing MaxEnt, and identified that the natural plague foci are primarily located in the Moiynqum, Betpaqdala, and Tauqum Deserts. The Zhambyl region's central part, including the Moiynqum and Sarysu districts, has a high potential risk of plague outbreak for the rural towns and villages. Since the phenomenon of climate change has been identified as a determinant that affects the rodent populations, thereby elevating the likelihood of an outbreak of plague, we investigated the potential dissemination routes of the disease under the changing climate conditions, thus creating Species Distribution Forecasts for the rodent species in southern part of Kazakhstan for the year 2100. By 2100, in case of increasing temperatures, the range of host species is likely to expand, leading to a higher risk of plague outbreaks. The highest risk of disease transmission can be expected at the outer limits of the modeled total distribution range, where infection rates are high, but antibody presence is low, making many species susceptible to the pathogen. To mitigate the risk of a potential plague outbreak, it is necessary to implement appropriate sanitary-epidemiological measures and climate mitigation policies.
Collapse
Affiliation(s)
- N. M. Rametov
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
- Institute of IonosphereAlmatyKazakhstan
- Department of Geospatial EngineeringSatpaev Kazakh National Research Technical UniversityAlmatyKazakhstan
| | - M. Steiner
- Department of Animal ScienceWageningen University and ResearchWageningenThe Netherlands
| | - N. A. Bizhanova
- Laboratory of TheriologyInstitute of ZoologyAlmatyKazakhstan
- Department of Biodiversity and BioresourcesAl‐Farabi Kazakh National UniversityAlmatyKazakhstan
- Wildlife Without Borders Public FundAlmatyKazakhstan
| | - Z. Zh. Abdel
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - D. T. Yessimseit
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - B. Z. Abdeliyev
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - R. S. Mussagalieva
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| |
Collapse
|
3
|
Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Diar-Bakerly N, Easom N, Echevarria C, Fuld J, Hart N, Hurst J, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Greening NJ, Heaney LG, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WDC, McCann GP, Neubauer S, Openshaw PJM, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Lewis KE, Thwaites RS, Briggs A, Docherty AB, Kerr S, Lone NI, Quint J, Sheikh A, Thorpe M, Zheng B, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Harrison EM, Wain LV, Brightling CE, Abel K, Adamali H, Adeloye D, Adeyemi O, Adrego R, Aguilar Jimenez LA, Ahmad S, Ahmad Haider N, Ahmed R, Ahwireng N, Ainsworth M, Al-Sheklly B, Alamoudi A, Ali M, Aljaroof M, All AM, Allan L, Allen RJ, Allerton L, Allsop L, Almeida P, Altmann D, Alvarez Corral M, Amoils S, Anderson D, Antoniades C, Arbane G, Arias A, Armour C, Armstrong L, Armstrong N, Arnold D, Arnold H, Ashish A, Ashworth A, Ashworth M, Aslani S, Assefa-Kebede H, Atkin C, Atkin P, Aung H, Austin L, Avram C, Ayoub A, Babores M, Baggott R, Bagshaw J, Baguley D, Bailey L, Baillie JK, Bain S, Bakali M, Bakau M, Baldry E, Baldwin D, Ballard C, Banerjee A, Bang B, Barker RE, Barman L, Barratt S, Barrett F, Basire D, Basu N, Bates M, Bates A, Batterham R, Baxendale H, Bayes H, Beadsworth M, Beckett P, Beggs M, Begum M, Bell D, Bell R, Bennett K, Beranova E, Bermperi A, Berridge A, Berry C, Betts S, Bevan E, Bhui K, Bingham M, Birchall K, Bishop L, Bisnauthsing K, Blaikely J, Bloss A, Bolger A, Bonnington J, Botkai A, Bourne C, Bourne M, Bramham K, Brear L, Breen G, Breeze J, Bright E, Brill S, Brindle K, Broad L, Broadley A, Brookes C, Broome M, Brown A, Brown A, Brown J, Brown J, Brown M, Brown M, Brown V, Brugha T, Brunskill N, Buch M, Buckley P, Bularga A, Bullmore E, Burden L, Burdett T, Burn D, Burns G, Burns A, Busby J, Butcher R, Butt A, Byrne S, Cairns P, Calder PC, Calvelo E, Carborn H, Card B, Carr C, Carr L, Carson G, Carter P, Casey A, Cassar M, Cavanagh J, Chablani M, Chambers RC, Chan F, Channon KM, Chapman K, Charalambou A, Chaudhuri N, Checkley A, Chen J, Cheng Y, Chetham L, Childs C, Chilvers ER, Chinoy H, Chiribiri A, Chong-James K, Choudhury N, Chowienczyk P, Christie C, Chrystal M, Clark D, Clark C, Clarke J, Clohisey S, Coakley G, Coburn Z, Coetzee S, Cole J, Coleman C, Conneh F, Connell D, Connolly B, Connor L, Cook A, Cooper B, Cooper J, Cooper S, Copeland D, Cosier T, Coulding M, Coupland C, Cox E, Craig T, Crisp P, Cristiano D, Crooks MG, Cross A, Cruz I, Cullinan P, Cuthbertson D, Daines L, Dalton M, Daly P, Daniels A, Dark P, Dasgin J, David A, David C, Davies E, Davies F, Davies G, Davies GA, Davies K, Dawson J, Daynes E, Deakin B, Deans A, Deas C, Deery J, Defres S, Dell A, Dempsey K, Denneny E, Dennis J, Dewar A, Dharmagunawardena R, Dickens C, Dipper A, Diver S, Diwanji SN, Dixon M, Djukanovic R, Dobson H, Dobson SL, Donaldson A, Dong T, Dormand N, Dougherty A, Dowling R, Drain S, Draxlbauer K, Drury K, Dulawan P, Dunleavy A, Dunn S, Earley J, Edwards S, Edwardson C, El-Taweel H, Elliott A, Elliott K, Ellis Y, Elmer A, Evans D, Evans H, Evans J, Evans R, Evans RI, Evans T, Evenden C, Evison L, Fabbri L, Fairbairn S, Fairman A, Fallon K, Faluyi D, Favager C, Fayzan T, Featherstone J, Felton T, Finch J, Finney S, Finnigan J, Finnigan L, Fisher H, Fletcher S, Flockton R, Flynn M, Foot H, Foote D, Ford A, Forton D, Fraile E, Francis C, Francis R, Francis S, Frankel A, Fraser E, Free R, French N, Fu X, Furniss J, Garner L, Gautam N, George J, George P, Gibbons M, Gill M, Gilmour L, Gleeson F, Glossop J, Glover S, Goodman N, Goodwin C, Gooptu B, Gordon H, Gorsuch T, Greatorex M, Greenhaff PL, Greenhalgh A, Greenwood J, Gregory H, Gregory R, Grieve D, Griffin D, Griffiths L, Guerdette AM, Guillen Guio B, Gummadi M, Gupta A, Gurram S, Guthrie E, Guy Z, H Henson H, Hadley K, Haggar A, Hainey K, Hairsine B, Haldar P, Hall I, Hall L, Halling-Brown M, Hamil R, Hancock A, Hancock K, Hanley NA, Haq S, Hardwick HE, Hardy E, Hardy T, Hargadon B, Harrington K, Harris E, Harrison P, Harvey A, Harvey M, Harvie M, Haslam L, Havinden-Williams M, Hawkes J, Hawkings N, Haworth J, Hayday A, Haynes M, Hazeldine J, Hazelton T, Heeley C, Heeney JL, Heightman M, Henderson M, Hesselden L, Hewitt M, Highett V, Hillman T, Hiwot T, Hoare A, Hoare M, Hockridge J, Hogarth P, Holbourn A, Holden S, Holdsworth L, Holgate D, Holland M, Holloway L, Holmes K, Holmes M, Holroyd-Hind B, Holt L, Hormis A, Hosseini A, Hotopf M, Howard K, Howell A, Hufton E, Hughes AD, Hughes J, Hughes R, Humphries A, Huneke N, Hurditch E, Husain M, Hussell T, Hutchinson J, Ibrahim W, Ilyas F, Ingham J, Ingram L, Ionita D, Isaacs K, Ismail K, Jackson T, James WY, Jarman C, Jarrold I, Jarvis H, Jastrub R, Jayaraman B, Jezzard P, Jiwa K, Johnson C, Johnson S, Johnston D, Jolley CJ, Jones D, Jones G, Jones H, Jones H, Jones I, Jones L, Jones S, Jose S, Kabir T, Kaltsakas G, Kamwa V, Kanellakis N, Kaprowska S, Kausar Z, Keenan N, Kelly S, Kemp G, Kerslake H, Key AL, Khan F, Khunti K, Kilroy S, King B, King C, Kingham L, Kirk J, Kitterick P, Klenerman P, Knibbs L, Knight S, Knighton A, Kon O, Kon S, Kon SS, Koprowska S, Korszun A, Koychev I, Kurasz C, Kurupati P, Laing C, Lamlum H, Landers G, Langenberg C, Lasserson D, Lavelle-Langham L, Lawrie A, Lawson C, Lawson C, Layton A, Lea A, Lee D, Lee JH, Lee E, Leitch K, Lenagh R, Lewis D, Lewis J, Lewis V, Lewis-Burke N, Li X, Light T, Lightstone L, Lilaonitkul W, Lim L, Linford S, Lingford-Hughes A, Lipman M, Liyanage K, Lloyd A, Logan S, Lomas D, Loosley R, Lota H, Lovegrove W, Lucey A, Lukaschuk E, Lye A, Lynch C, MacDonald S, MacGowan G, Macharia I, Mackie J, Macliver L, Madathil S, Madzamba G, Magee N, Magtoto MM, Mairs N, Majeed N, Major E, Malein F, Malim M, Mallison G, Mandal S, Mangion K, Manisty C, Manley R, March K, Marciniak S, Marino P, Mariveles M, Marouzet E, Marsh S, Marshall B, Marshall M, Martin J, Martineau A, Martinez LM, Maskell N, Matila D, Matimba-Mupaya W, Matthews L, Mbuyisa A, McAdoo S, Weir McCall J, McAllister-Williams H, McArdle A, McArdle P, McAulay D, McCormick J, McCormick W, McCourt P, McGarvey L, McGee C, Mcgee K, McGinness J, McGlynn K, McGovern A, McGuinness H, McInnes IB, McIntosh J, McIvor E, McIvor K, McLeavey L, McMahon A, McMahon MJ, McMorrow L, Mcnally T, McNarry M, McNeill J, McQueen A, McShane H, Mears C, Megson C, Megson S, Mehta P, Meiring J, Melling L, Mencias M, Menzies D, Merida Morillas M, Michael A, Milligan L, Miller C, Mills C, Mills NL, Milner L, Misra S, Mitchell J, Mohamed A, Mohamed N, Mohammed S, Molyneaux PL, Monteiro W, Moriera S, Morley A, Morrison L, Morriss R, Morrow A, Moss AJ, Moss P, Motohashi K, Msimanga N, Mukaetova-Ladinska E, Munawar U, Murira J, Nanda U, Nassa H, Nasseri M, Neal A, Needham R, Neill P, Newell H, Newman T, Newton-Cox A, Nicholson T, Nicoll D, Nolan CM, Noonan MJ, Norman C, Novotny P, Nunag J, Nwafor L, Nwanguma U, Nyaboko J, O'Donnell K, O'Brien C, O'Brien L, O'Regan D, Odell N, Ogg G, Olaosebikan O, Oliver C, Omar Z, Orriss-Dib L, Osborne L, Osbourne R, Ostermann M, Overton C, Owen J, Oxton J, Pack J, Pacpaco E, Paddick S, Painter S, Pakzad A, Palmer S, Papineni P, Paques K, Paradowski K, Pareek M, Parfrey H, Pariante C, Parker S, Parkes M, Parmar J, Patale S, Patel B, Patel M, Patel S, Pattenadk D, Pavlides M, Payne S, Pearce L, Pearl JE, Peckham D, Pendlebury J, Peng Y, Pennington C, Peralta I, Perkins E, Peterkin Z, Peto T, Petousi N, Petrie J, Phipps J, Pimm J, Piper Hanley K, Pius R, Plant H, Plein S, Plekhanova T, Plowright M, Polgar O, Poll L, Porter J, Portukhay S, Powell N, Prabhu A, Pratt J, Price A, Price C, Price C, Price D, Price L, Price L, Prickett A, Propescu J, Pugmire S, Quaid S, Quigley J, Qureshi H, Qureshi IN, Radhakrishnan K, Ralser M, Ramos A, Ramos H, Rangeley J, Rangelov B, Ratcliffe L, Ravencroft P, Reddington A, Reddy R, Redfearn H, Redwood D, Reed A, Rees M, Rees T, Regan K, Reynolds W, Ribeiro C, Richards A, Richardson E, Rivera-Ortega P, Roberts K, Robertson E, Robinson E, Robinson L, Roche L, Roddis C, Rodger J, Ross A, Ross G, Rossdale J, Rostron A, Rowe A, Rowland A, Rowland J, Roy K, Roy M, Rudan I, Russell R, Russell E, Saalmink G, Sabit R, Sage EK, Samakomva T, Samani N, Sampson C, Samuel K, Samuel R, Sanderson A, Sapey E, Saralaya D, Sargant J, Sarginson C, Sass T, Sattar N, Saunders K, Saunders P, Saunders LC, Savill H, Saxon W, Sayer A, Schronce J, Schwaeble W, Scott K, Selby N, Sewell TA, Shah K, Shah P, Shankar-Hari M, Sharma M, Sharpe C, Sharpe M, Shashaa S, Shaw A, Shaw K, Shaw V, Shelton S, Shenton L, Shevket K, Short J, Siddique S, Siddiqui S, Sidebottom J, Sigfrid L, Simons G, Simpson J, Simpson N, Singh C, Singh S, Sissons D, Skeemer J, Slack K, Smith A, Smith D, Smith S, Smith J, Smith L, Soares M, Solano TS, Solly R, Solstice AR, Soulsby T, Southern D, Sowter D, Spears M, Spencer LG, Speranza F, Stadon L, Stanel S, Steele N, Steiner M, Stensel D, Stephens G, Stephenson L, Stern M, Stewart I, Stimpson R, Stockdale S, Stockley J, Stoker W, Stone R, Storrar W, Storrie A, Storton K, Stringer E, Strong-Sheldrake S, Stroud N, Subbe C, Sudlow CL, Suleiman Z, Summers C, Summersgill C, Sutherland D, Sykes DL, Sykes R, Talbot N, Tan AL, Tarusan L, Tavoukjian V, Taylor A, Taylor C, Taylor J, Te A, Tedd H, Tee CJ, Teixeira J, Tench H, Terry S, Thackray-Nocera S, Thaivalappil F, Thamu B, Thickett D, Thomas C, Thomas S, Thomas AK, Thomas-Woods T, Thompson T, Thompson AAR, Thornton T, Tilley J, Tinker N, Tiongson GF, Tobin M, Tomlinson J, Tong C, Touyz R, Tripp KA, Tunnicliffe E, Turnbull A, Turner E, Turner S, Turner V, Turner K, Turney S, Turtle L, Turton H, Ugoji J, Ugwuoke R, Upthegrove R, Valabhji J, Ventura M, Vere J, Vickers C, Vinson B, Wade E, Wade P, Wainwright T, Wajero LO, Walder S, Walker S, Walker S, Wall E, Wallis T, Walmsley S, Walsh JA, Walsh S, Warburton L, Ward TJC, Warwick K, Wassall H, Waterson S, Watson E, Watson L, Watson J, Welch C, Welch H, Welsh B, Wessely S, West S, Weston H, Wheeler H, White S, Whitehead V, Whitney J, Whittaker S, Whittam B, Whitworth V, Wight A, Wild J, Wilkins M, Wilkinson D, Williams N, Williams N, Williams J, Williams-Howard SA, Willicombe M, Willis G, Willoughby J, Wilson A, Wilson D, Wilson I, Window N, Witham M, Wolf-Roberts R, Wood C, Woodhead F, Woods J, Wormleighton J, Worsley J, Wraith D, Wrey Brown C, Wright C, Wright L, Wright S, Wyles J, Wynter I, Xu M, Yasmin N, Yasmin S, Yates T, Yip KP, Young B, Young S, Young A, Yousuf AJ, Zawia A, Zeidan L, Zhao B, Zongo O. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10:761-775. [PMID: 35472304 PMCID: PMC9034855 DOI: 10.1016/s2213-2600(22)00127-8] [Citation(s) in RCA: 144] [Impact Index Per Article: 72.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/23/2022] [Accepted: 03/31/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge. METHODS The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing. FINDINGS 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters. INTERPRETATION The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials. FUNDING UK Research and Innovation and National Institute for Health Research.
Collapse
|
4
|
O'Keefe K, Elliott A, Livasy C, Steiner M, Kang I, Hoon DSB, Korn WM, Walker P, Radovich M, Pohlmann PR, Swain SM, Tan AR, Heeke AL. HER2 alterations and prognostic implications in all subtypes of breast cancer. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.1041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1041 Background: Amplification or overexpression of human epidermal growth factor receptor 2 (HER2) oncogene is present in about 15-20% of breast cancers & is a prognostic & predictive biomarker. Additional ERBB2/HER2 alterations have become apparent on tumor next generation sequencing (NGS), including activating kinase domain mutations & fusions. Methods: DNA NGS (592 gene panel or whole exome) data from 12,153 breast samples retrospectively reviewed for ERBB2 alterations with RNA whole-transcriptome sequencing (WTS) data available for 7289 (60%) samples. Gene fusions detected using the ArcherDx fusion assay or WTS. Clinicopathologic features were described including breast cancer subtype, age, & biopsy site. HER2 status determined according to 2018 ASCO-CAP guideline. Overall survival obtained from insurance claims & Kaplan-Meier estimates were calculated for defined patient (pt) cohorts. Statistical significance was determined using Chi-square & Wilcoxon rank sum tests. Results: ERBB2 mutations ( ERBB2mts) were identified in 3.2% (n = 388) of tumors overall & most common in liver metastases (113/1972, 5.7%). ERBB2mts were found more in breast lobular tumors compared to ductal tumors (10 vs 2.1%, p < 0.001). HER2+ tumors had higher frequency of ERBB2mts compared to HER2- (4.3 vs 3%, p = 0.028). Tumors with score of 0 by immunohistochemistry demonstrated lower rate of ERBB2mts (0+ 2.2%, 1+ 3.5%, 2+ 4.5%, 3+ 3.45%, p < 0.05). Among HER2- tumors, ERBB2mts were present in 3.6% of hormone receptor (HR)+/HER2- & 1.9% of TNBC. Metastatic tumors had a higher rate of ERBB2mts compared to locoregional breast tumors (3.8 vs 2%, p < 0.001), with increased rates of activating mutations S310F (0.1 vs 0.0%, p < 0.05) & D769H (0.3 vs 0.1%, p < 0.05), & the resistance mutation L755S (1.2 vs 0.6%, p < 0.01). Compared to ERBB2-WT, ERRB2mts were associated with decreased ERBB2 transcripts levels in HER2+ samples (222 vs 441 transcripts per million [TPM], p < 0.001) & increased levels in HER2- samples (73 vs 35 TPM, p < 0.001). High tumor mutational burden (≥ 10 mut/Mb) & ERBB3 mutations were more common in ERBB2mts compared to ERRB2-WT (16.7 vs 7.7%, p < 0.001; 10.6 vs 0.8%, p < 0.001). ERBB2 fusions were rare (0.49%) with 97% occurring in HER2+ tumors. Of 8358 pts with outcome data, prognosis (HR 1.2, P = 0.06) & response to chemotherapy (HR 1.1, P = 0.42) was similar between pts with HER2- ERBB2mt & ERBB2-WT. Conclusions: ERBB2mts & fusions were observed in all breast cancer subtypes - more commonly in HER2+, metastatic, & lobular histology tumors - & did not influence prognosis. These alterations may reflect response to treatment pressures in HER2+ disease to reactivate HER2-mediated growth pathways following anti-HER2 therapy & may represent a targetable upregulated oncogenic pathway in HER2- disease. Ongoing identification of ERBB2 alterations may augment treatment options for breast cancer pts & clinical outcomes from this approach are under investigation.
Collapse
Affiliation(s)
| | | | - Chad Livasy
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| | | | - Irene Kang
- Division of Oncology, USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA
| | - Dave S. B. Hoon
- Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA
| | | | | | | | | | - Sandra M. Swain
- Georgetown University Medical Center and MedStar Health, Washington, DC
| | | | | |
Collapse
|
5
|
Palmieri C, Linden H, Birrell S, Lim E, Schwartzberg L, Rugo H, Cobb P, Jain K, Vogel C, O'Shaughnessy J, Johnston S, Getzenberg R, Barnette K, Steiner M, Brufsky A, Overmoyer B. 100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
6
|
Steiner M, Tan AR. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Clin Adv Hematol Oncol 2021; 19:305-315. [PMID: 33989278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. Immune checkpoint inhibitors (ICIs) are now available to treat patients with advanced TNBC who have programmed cell death ligand 1 (PD-L1)-positive tumors; these agents have been shown to improve clinical outcomes. Additionally, long-term disease control can be achieved in a subset of patients. Continued investigations of ICIs and optimal combinations with chemotherapy and targeted agents to enhance the immune response are ongoing, along with studies aimed at identifying the patients most likely to benefit. For early-stage TNBC, the data to date on administering ICI-based combination therapies in the neoadjuvant setting are compelling and suggest that the benefit from immunotherapy does not depend on PD-L1 expression. This review will discuss the clinical trial data on ICIs as monotherapy and in combination with chemotherapy in the treatment of patients with metastatic and early-stage TNBC.
Collapse
Affiliation(s)
- Meghan Steiner
- Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Antoinette R Tan
- Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| |
Collapse
|
7
|
Steiner M, Huettmann F. Justification for a taxonomic conservation update of the rodent genus Tamiasciurus: addressing marginalization and mis-prioritization of research efforts and conservation laissez-faire for a sustainability outlook. The European Zoological Journal 2021. [DOI: 10.1080/24750263.2020.1857852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- M. Steiner
- Institute for Arctic Biology, Department of Conservation Ecology, EWHALE Lab, University of Alaska Fairbanks, Fairbanks, AK, USA
| | - F. Huettmann
- Institute for Arctic Biology, Department of Conservation Ecology, EWHALE Lab, University of Alaska Fairbanks, Fairbanks, AK, USA
| |
Collapse
|
8
|
Magnes T, Wagner S, Thorner AR, Neureiter D, Klieser E, Rinnerthaler G, Weiss L, Huemer F, Zaborsky N, Steiner M, Weis S, Greil R, Egle A, Melchardt T. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. ESMO Open 2021; 6:100012. [PMID: 33399078 PMCID: PMC7807834 DOI: 10.1016/j.esmoop.2020.100012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/05/2020] [Accepted: 11/10/2020] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND The prognosis of patients with secondary central nervous system lymphoma (SCNSL) is poor and despite massive advances in understanding the mutational landscape of primary diffuse large B-cell lymphoma (DLBCL), the genetic comparison to SCNSL is still lacking. We therefore collected paired samples from six patients with DLBCL with available biopsies from a lymph node (LN) at primary diagnosis and the central nervous system (CNS) at recurrence. PATIENTS AND METHODS A targeted, massively parallel sequencing approach was used to analyze 216 genes recurrently mutated in DLBCL. Healthy tissue from each patient was also sequenced in order to exclude germline mutations. The results of the primary biopsies were compared with those of the CNS recurrences to depict the genetic background of SCNSL and evaluate clonal evolution. RESULTS Sequencing was successful in five patients, all of whom had at least one discordant mutation that was not detected in one of their samples. Four patients had mutations that were found in the CNS but not in the primary LN. Discordant mutations were found in genes known to be important in lymphoma biology such as MYC, CARD11, EP300 and CCND3. Two patients had a Jaccard similarity coefficient below 0.5 indicating substantial genetic differences between the primary LN and the CNS recurrence. CONCLUSIONS This analysis gives an insight into the genetic landscape of SCNSL and confirms the results of our previous study on patients with systemic recurrence of DLBCL with evidence of substantial clonal diversification at relapse in some patients, which might be one of the mechanisms of treatment resistance.
Collapse
Affiliation(s)
- T Magnes
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | - S Wagner
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | - A R Thorner
- Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, USA
| | - D Neureiter
- Department of Pathology, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - E Klieser
- Department of Pathology, Paracelsus Medical University, Salzburg, Austria
| | - G Rinnerthaler
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - L Weiss
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - F Huemer
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - N Zaborsky
- Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - M Steiner
- Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - S Weis
- Division of Neuropathology, Department of Pathology and Neuropathology, Kepler University Hospital and School of Medicine, Johannes Kepler University, Linz, Austria
| | - R Greil
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - A Egle
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - T Melchardt
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.
| |
Collapse
|
9
|
Esteban-Ortega MM, Steiner M, García-Lozano I, Thuissard-Vasallo I, Moriche-Carretero M, Muñoz-Fernández S. Reproducibility of manual choroidal thickness measurements using optical coherence tomography. ACTA ACUST UNITED AC 2020; 95:379-385. [PMID: 32532593 DOI: 10.1016/j.oftal.2020.03.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Revised: 03/01/2020] [Accepted: 03/02/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE Spectral-domain optical coherence tomography (SD-OCT) is the most useful tool to measure choroidal thickness (CT). CT may be increased in ocular and systemic diseases. However, there are concerns relating reproducibility and external validity of OCT. The aim of this study was to assess the inter-observer and intra-observer variability of manual OCT measurements. METHODS CT was manually measured in the central choroid of 40 eyes from 21 subjects (11 healthy and 10 with ankylosing spondylitis) using RTVue-100 OCT (Optovue Inc., Fremont, CA, EE.UU.). Measurements were performed by 9 independent ophthalmologists from 6 different centers. To assess the inter-observer variability, the intra-class correlation coefficient (ICC) method was calculated. Also, intra-observer variability was assessed in 2 of the ophthalmologists. RESULTS The mean subfoveal CT was 364.9±85.1μm (range, 170 to 572). The inter-observer ICC was 0.823 (CI 95%, 0.749 to 0.888, p<0.001). The intra-observer ICCs were 0.885 (CI 95%, 0.783 to 0.939, p<0.001) and 0.925 (CI 95%, 0.859 to 0.960. p<0.001). CONCLUSIONS In this study, manual measurements of CT with OCT showed a good concordance. These results suggest that manual OCT is a valid tool for multicenter studies.
Collapse
Affiliation(s)
- M M Esteban-Ortega
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - M Steiner
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España; Sección de Reumatología, Hospital Universitario Infanta Sofía, Madrid, España.
| | - I García-Lozano
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - I Thuissard-Vasallo
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - M Moriche-Carretero
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - S Muñoz-Fernández
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España; Sección de Reumatología, Hospital Universitario Infanta Sofía, Madrid, España
| | | |
Collapse
|
10
|
Steiner M, Esteban-Ortega MDM, Thuissard-Vasallo I, García-Lozano I, García J, Perez-Blazquez E, Sambricio J, García-Aparicio Á, Casco-Silva BF, Sanz J, Valdés-Sanz N, Fernandez-Espartero C, Díaz-Valle T, Gurrea-Almela M, Fernández-Leroy J, Gómez-Resa M, Pato E, Díaz Valle D, Méndez-Fernández R, Navio Marco MT, Muñoz-Fernández S. AB0726 CHOROIDAL THICKNESS IS A BIOMARKER AND CAN PREDICT THE RESPONSE TO TREATMENT IN ANKYLOSING SPONDYLITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Choroidal thickness (CT) has been proposed and evaluated as a potential marker of systemic inflammation associated with inflammatory diseases as Ankylosing spondylitis (AS). Patients with active AS have a thicker choroid than healthy subjects, regardless of eye inflammation. The evolution of choroid after treatment is poorly known.Objectives:This study evaluates the CT of patients with severe AS disease activity before and after six months of biological therapy.Methods:This prospective multicenter study evaluates the CT in 44 patients with high AS disease activity, naïve for biological treatment, and no history of eye inflammation before and after six months of biological therapy, aged from 18 to 65 years. The correlations between the CT and C-reactive protein (CRP) with the disease activity indices and scales as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), night pain and Patient Global Assessment (PGA) were calculated at baseline and after six months of biological therapy. The concordance between the CT and CRP was determined. Finally, we assessed potential predictors of response to treatment. Clinically important improvement was defined as a decrease in ASDAS score ≥ 1.1 points.Results:Globally, 44 eyes of 44 patients aged between 18-65 years were included in the study, 12 (27%) women. The biological treatments prescribed were: Adalimumab 13 (29.5%), Certolizumab 9 (20.5%), Secukinumab 10 (20%), Etanercept 8 (18%), Infliximab 3 (6.8%), and Golimumab 1 (2.2%).Mean CT values were significantly higher at baseline than after six months of treatment (baseline 355.28±80.46 µm; 6 months, 341.26±81.06 µm) (p<0.001).CT decreased both in patients on biological treatment without effect in eye (Secukinumab and Etanecept; p=0.024) and in patients on treatment with effect in eye (other; p=0.005). Also, CRP, BASDAI, night pain and PGA decreased after six months of treatment ((p<0.001, p<0.001, p<0.001, p<0.001). We found a 95% concordance between CT and CRP at baseline and 6 months.Multivariable analysis showed that clinically important improvement was associated with higher CT and age as independent factors (OR 0.97, CI95% 0.91-0.93; p=0.009, and OR 0.81, CI95% 0.7-0.95; p=0.005). Clinically important improvement was associated with basal CT >374 µm (sensitivity 78 %, [CI 95% 60-90], specificity 78% [CI 95% 52-92], area under the curve of ROC, 0.70, likelihood ratio 3.6).Conclusion:CT decreased significantly after six months of biological treatment. CT and CPR had a 95% concordance. A high CT is associated with risk of failure to biological treatment. CT can be considered as a useful biomarker of inflammation and predictor of response to treatment in AS.References:[1]Karkucak M, Kalkisim A, Kola M, et al. SAT0408 anti Tnf-α therapy provides beneficial effects on choroidal thickness increase in patients with active ankylosing spondylitis: a possible mechanism of infliximab effectiveness in suppressing uveitis attacks.Ann Rheum Dis. 2016;75:817.Disclosure of Interests:None declared
Collapse
|
11
|
Flores-Orozco A, Gallistl J, Steiner M, Brandstätter C, Fellner J. Mapping biogeochemically active zones in landfills with induced polarization imaging: The Heferlbach landfill. Waste Manag 2020; 107:121-132. [PMID: 32279051 DOI: 10.1016/j.wasman.2020.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 03/28/2020] [Accepted: 04/01/2020] [Indexed: 06/11/2023]
Abstract
In this study, we investigate the applicability of the Induced Polarization (IP) imaging method to discriminate between biogeochemically active and inactive areas of a landfill. The elevated amount of degradable organic carbon in landfills results in the development of biogeochemical hot-spots associated with high rates of microbial activity and the generation of landfill gas and leachate as metabolic products. Our results demonstrate that the electrical conductivity is mainly sensitive to the increase in the fluid conductivity associated to leachate production and migration. Whereas images of the polarization effect, expressed in terms of the imaginary component (σ″) or the phase of the complex conductivity (ϕ), reveal the potential to characterize variations in the architecture and biogeochemical activity of the landfill. Correspondingly, biogeochemically active zones (leachable TOC contents above 1500 mg/kg dry waste) are related to high polarization values (σ″ > 10 mS/m, ϕ > 40 mrads), whereas low leachable TOC contents (<300 mg/kg dry waste) in the inactive areas are characterized by low polarization values (σ″ < 1 mS/m, 10 < ϕ < 25). Additionally, landfill sections corresponding to construction and demolition waste (CDW), associated to negligible TOC content, exhibit the lowest polarization response (σ″ < 0.1 mS/m, ϕ < 15). We prove that IP imaging is a well-suited method for landfill investigations that permits an improved characterization of landfill geometry, variation in waste composition, and the discrimination between biogeochemically active and inactive zones.
Collapse
Affiliation(s)
- A Flores-Orozco
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria.
| | - J Gallistl
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria
| | - M Steiner
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria
| | - C Brandstätter
- TU Wien, Institute for Water Quality and Resource Management, Austria
| | - J Fellner
- TU Wien, Institute for Water Quality and Resource Management, Austria
| |
Collapse
|
12
|
Cost KT, Unternaehrer E, Jonas W, Gaudreau H, Bouvette-Tourcot A, Steiner M, Lydon J, Szatmari P, Meaney M, Fleming A. Once and Again: Intergenerational Transmission of Parenting. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2017.01.147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionAnimal and human studies suggest that individual differences in maternal parenting behaviour are transmitted from one generation to the next.ObjectiveThis study aimed to examine potential psychosocial mechanisms underlying an intergenerational transmission of conceptualization of parenting, including affect, cognition, and parental support.MethodsIn a subsample of 201 first-time mothers participating in the Maternal Adversity, Vulnerability and Neurodevelopment (MAVAN) project, we assessed maternal childhood rearing experiences, using the Parental Bonding Instrument and the Childhood Trauma Questionnaire. At 6 months postpartum, mothers completed questionnaires on parenting stress, symptoms of depression, internalization of maternal care regulation and current relationship with mother and father.ResultsWe found significant direct associations of maltreatment and rearing by the grandmother with parenting stress at 6 months. These associations were mediated through distinct psychosocial pathways: the association of maltreatment on higher parenting stress was fully mediated through more maternal symptoms of depression (z = 2.297; P = 022). The association between sub-optimal rearing provided by the mother and higher parenting stress was mediated through lower internalization of maternal care regulation (z = -2.155; P = 031) and to a lesser degree through more symptoms of depression (z = -1.842; P = 065). Finally, higher quality rearing by the grandfather was indirectly related to lower parenting stress through positive current relationship with the father (z = -2.617; P = 009).ConclusionsThere are distinct pathways by which early experiences manifest in parenting stress. By understanding the structure of dysregulated parenting, clinicians will have practical information to specifically target maternal motivation, social supports, and depressed mood to disrupt maladaptive parenting cognitions and practices.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
13
|
Cézard G, Gruer L, Steiner M, Douglas A, Davis C, Buchanan D, Katikireddi SV, Millard A, Sheikh A, Bhopal R. Ethnic variations in falls and road traffic injuries resulting in hospitalisation or death in Scotland: the Scottish Health and Ethnicity Linkage Study. Public Health 2020; 182:32-38. [PMID: 32151824 PMCID: PMC7294220 DOI: 10.1016/j.puhe.2020.01.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 01/09/2020] [Accepted: 01/23/2020] [Indexed: 02/05/2023]
Abstract
Objectives To investigate ethnic differences in falls and road traffic injuries (RTIs) in Scotland. Study design A retrospective cohort of 4.62 million people, linking the Scottish Census 2001, with self-reported ethnicity, to hospitalisation and death records for 2001–2013. Methods We selected cases with International Classification of Diseases–10 diagnostic codes for falls and RTIs. Using Poisson regression, age-adjusted risk ratios (RRs, multiplied by 100 as percentages) and 95% confidence intervals (CIs) were calculated by sex for 10 ethnic groups with the White Scottish as reference. We further adjusted for country of birth and socio-economic status (SES). Results During about 49 million person-years, there were 275,995 hospitalisations or deaths from fall-related injuries and 43,875 from RTIs. Compared with the White Scottish, RRs for falls were higher in most White and Mixed groups, e.g., White Irish males (RR: 131; 95% CI: 122–140) and Mixed females (126; 112–143), but lower in Pakistani males (72; 64–81) and females (72; 63–82) and African females (79; 63–99). For RTIs, RRs were higher in other White British males (161; 147–176) and females (156; 138–176) and other White males (119; 104–137) and females (143; 121–169) and lower in Pakistani females (74; 57–98). The ethnic variations differed by road user type, with few cases among non-White motorcyclists and non-White female cyclists. The RRs were minimally altered by adjustment for country of birth or SES. Conclusion We found important ethnic variations in injuries owing to falls and RTIs, with generally lower risks in non-White groups. Culturally related differences in behaviour offer the most plausible explanation, including variations in alcohol use. The findings do not point to the need for new interventions in Scotland at present. However, as the ethnic mix of each country is unique, other countries could benefit from similar data linkage-based research. Ethnic inequalities in injuries are demonstrated in Scotland based on a large sample size and a fine ethnic granularity. White minority ethnic groups had the highest risks of fall-related injuries in Scotland. Fall-related injuries were the least likely in the Pakistani population. Ethnic differences in road traffic injuries varied by the type of road user. Ethnic differences in injuries were not explained by socio-economic status or country of birth.
Collapse
Affiliation(s)
- G Cézard
- School of Geography and Sustainable Development, University of St Andrews, St Andrews, UK; Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
| | - L Gruer
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - M Steiner
- Environmental & Occupational Medicine, Section of Population Health, University of Aberdeen, Aberdeen, UK
| | - A Douglas
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - C Davis
- Information Services Division (ISD), NHS National Services Scotland, Edinburgh, UK
| | - D Buchanan
- Information Services Division (ISD), NHS National Services Scotland, Edinburgh, UK
| | - S V Katikireddi
- MRC Social & Public Health Sciences Unit, Evaluation of Social Interventions Programme, University of Glasgow, Glasgow, UK
| | - A Millard
- NHS Health Scotland, Directorate of Public Health Science, Glasgow, UK
| | - A Sheikh
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - R Bhopal
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
14
|
Kabai E, Poppitz-Spuhler A, Savkin BT, Steiner M. Retrospective analysis of Sr-90 in roe deer antlers originating from north-west Germany. J Radioanal Nucl Chem 2019. [DOI: 10.1007/s10967-019-06914-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Tucher N, Höhn O, Murthy JN, Martinez JC, Steiner M, Armbruster A, Lorenz E, Bläsi B, Goldschmidt JC. Energy yield analysis of textured perovskite silicon tandem solar cells and modules. Opt Express 2019; 27:A1419-A1430. [PMID: 31684495 DOI: 10.1364/oe.27.0a1419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 07/12/2019] [Indexed: 05/18/2023]
Abstract
Perovskite silicon tandem solar cells combine potentially low production costs with the ability to surpass the efficiency limit of silicon single junction solar cells. Optical modeling and optimization are crucial to achieve this ambitious goal in the near future. The optimization should seek to maximize the energy yield based on realistic environmental conditions. This work analyzes the energy yield of perovskite silicon tandem solar cells and modules based on realistic experimental data, with a special focus on the investigation of surface textures at the front and rear side of the solar cell and its implication for reflection as well as parasitic absorption properties. The investigation reveals a 7.3%rel higher energy yield for an encapsulated tandem cell with a textured front side compared with an encapsulated high efficiency single junction solar cell with 24.3% harvesting efficiency for irradiance data of the year 2014 in Freiburg/Germany.
Collapse
|
16
|
Steiner M, Veneris JT, Lastra R, Weroha SJ, Hou X, Maurer MJ, Heinzen EP, Oberg AL, Fleming GF, Conzen SD. Glucocorticoid receptor expression in Müllerian carcinosarcomas. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e17038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17038 Background: Carcinosarcomas (CS) are aggressive gynecologic malignancies defined by a biphasic tumor histology of carcinomatous and sarcomatous components. High expression of glucocorticoid receptor (GR) is associated with aggressive tumor biology in triple-negative breast, ovarian, and endometrial cancers. GR activation results in transcriptional regulation of epithelial-mesenchymal transition (EMT) genes. Therefore, we hypothesized that the sarcomatous component of Müllerian CS may be associated with relatively higher GR expression compared to the carcinomatous portion. Methods: Müllerian CSs from the University of Chicago tissue bank diagnosed from 5/19/2009 8/25/2014 were identified and pathology confirmed (RL). In addition, we evaluated GR expression in a mouse PDX CS model. Immunohistochemical expression of nuclear estrogen (ER), progesterone (PR), androgen (AR), and GR was quantified using the H-score. Scores between the sarcomatous and carcinomatous components were compared using a paired t-test. Results: Mean GR H-score was relatively higher in the sarcomatous vs carcinomatous component, overall (144.44 vs 38.89, P = 0.0014). Mean H-score also differed between sarcomatous and carcinomatous components for ER (3.06 vs 63.06, P = 0.016), PR (1.67 vs 47.22, P = 0.004), and AR (0 vs 2.78, P = 0.056). The significantly higher sarcomatous GR expression was replicated in IHC evaluation of the mouse PDX model. Conclusions: GR expression is significantly higher in the sarcomatous than the carcinomatous component of Müllerian CS, while ER, PR, and AR expression is significantly lower. Recent data suggest that an EMT gene signature is more prominently expressed in the sarcomatous versus carcinomatous component. We hypothesize that GR expression and activity may mediate EMT gene expression and represent a therapeutic target for CS. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Suzanne D. Conzen
- Section of Hematology-Oncology, University of Chicago Medical Center, Chicago, IL
| |
Collapse
|
17
|
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol 2019; 154:199-206. [PMID: 30987772 DOI: 10.1016/j.ygyno.2019.04.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 04/03/2019] [Accepted: 04/07/2019] [Indexed: 12/28/2022]
Abstract
OBJECTIVE Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. METHODS DNA from FFPE tumor tissue obtained during routine clinical care for 9645 gynecologic malignancies (ovary, fallopian tube, uterus, cervix, vagina, vulvar, and placenta) was analyzed for all classes of genomic alterations (base substitutions (muts), insertions, deletions, rearrangements, and amplifications) in ESR1 by hybrid capture next generation sequencing. A subset of alterations was characterized in laboratory-based transcription assays for response to endocrine therapies. RESULTS A total of 295 ESR1 genomic alterations were identified in 285 (3.0%) cases. mutESR1 were present in 86 (0.9%) cases and were more common in uterine compared to other cancers (2.0% vs <1%, respectively p < 0.001). mutESR1 were enriched in carcinomas with endometrioid versus serous histology (4.4% vs 0.2% respectively, p < 0.0001 in uterine and 3.5% vs 0.3% respectively, p = 0.0004 in ovarian carcinomas). In three of four patients with serial sampling, mutESR1 emerged under the selective pressure of AI therapy. Despite decreased potency of estrogen receptor (ER) antagonists in transcriptional assays, clinical benefit was observed following treatment with selective ER-targeted therapy, in one case lasting >48 months. CONCLUSIONS While the prevalence of ESR1 mutations in gynecologic malignancies is low, there are significant clinical implications useful in guiding therapeutic approaches for these cancers.
Collapse
Affiliation(s)
- Stéphanie L Gaillard
- Duke University Medical Center, Durham, NC, United States of America; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, United States of America.
| | | | - Laurie M Gay
- Foundation Medicine, Inc., Cambridge, MA, United States of America
| | - Meghan Steiner
- Duke University Medical Center, Durham, NC, United States of America
| | | | | | | | | | - Fidel A Valea
- Duke University Medical Center, Durham, NC, United States of America
| | | | | | - Ching-Yi Chang
- Duke University Medical Center, Durham, NC, United States of America
| | | | - Andrew Berchuck
- Duke University Medical Center, Durham, NC, United States of America
| | - Julia A Elvin
- Duke University Medical Center, Durham, NC, United States of America
| |
Collapse
|
18
|
Gampenrieder SP, Angela R, Rinnerthaler G, Hackl H, Steiner M, Pulverer W, Weinhaeusel A, Klinglmayr E, Karl T, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Biomarkers predicting response to bevacizumab containing therapy in metastatic breast cancer (MBC) are of urgent need. In a retrospective single-institution analysis we have previously shown that a 3-gene methylation signature (MLH1,POLKand TMBIM6) could discriminate between responders and non-responders to a bevacizumab-based therapy in two independent cohorts of patients with MBC with an AUC of 0.94 and 0.86, respectively (Gampenrieder SP et al. Theranostics. 2018. 8(8):2278-2288). Here, we present the validation of these findings within the prospective phase III trial TANIA (Vrdoljak E et al. Ann Oncol. 2016. 27(11):2046-52) randomizing 494 patients with HER2-negative MBC to chemotherapy plus bevacizumab or chemotherapy alone for two consecutive treatment lines (second- and third-line). All patients had already received bevacizumab-containing therapy in the first-line setting.
Patients and methods: DNA isolated from archival FFPE tumor samples was available from 200 patients consenting to optional translational research within the TANIA trial. Out of these, 176 samples were collected prior to first-line bevacizumab therapy and were analyzed retrospectively. Sufficient DNA for methylation analysis was available from 124 patients: 64 treated with chemotherapy plus bevacizumab and 60 treated with chemotherapy alone. All samples were isolated from the primary tumor. Quantitative methylation analysis was performed by pyrosequencing on the PyroMark Q24 Advanced System (Qiagen). PFS and OS analyses were performed in both study arms comparing “predicted responders” (PRED_R) versus “predicted non-responders” (PRED_NR) based either on median dichotomization or according to the cutoffs for individual CpG and the combined 3-CpG methylation logistic regression model.
Results:Out of the 124 evaluable patients, 32 (25.8%) were classified as PRED_R and 92 as RED_NR by the 3-gene methylation signature. PRED_R did not have a significantly different second-line PFS (HR 0.95, 95%CI 0.57-1.57; P = 0.84) or OS (HR 0.91, 95%CI 0.51-1.60; P = 0.73) when treated in the bevacizumab-containing study arm compared to PRED_NR. In addition, PRED_R did not show a longer PFS when treated with bevacizumab compared to PRED_R treated with chemotherapy alone (HR 0.95, 95%CI 0.59-1.54; P = 0.83). Furthermore, there was no difference in third-line PFS and the combination of second- and third-line PFS between PRED_R and PRED-NR in the bevacizumab arm. In the control arm, PRED_NR showed a statistically significant shorter PFS compared to PRED_R (HR 0.50, 95%CI 0.22-0.77; P = 0.006), but not OS (HR 0.95, 95%CI 0.51-1.77; P = 0.86).
Conclusion: Our 3-gene methylation signature was not confirmed as predictive biomarker for bevacizumab efficacy in metastatic breast cancer.
(This research project was partially supported by ROCHE Austria GmbH)
Citation Format: Gampenrieder SP, Angela R, Rinnerthaler G, Hackl H, Steiner M, Pulverer W, Weinhaeusel A, Klinglmayr E, Karl T, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-07.
Collapse
Affiliation(s)
- SP Gampenrieder
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - R Angela
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - G Rinnerthaler
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - H Hackl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - M Steiner
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - W Pulverer
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Weinhaeusel
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - E Klinglmayr
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - T Karl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - S Ilic
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - C Hufnagl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - C Hauser-Kronberger
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Egle
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - R Greil
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| |
Collapse
|
19
|
Dama M, Mahoney JL, Van Lieshout RJ, Frey BN, Steiner M. The Menopause Visual Analogue Scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition. Climacteric 2018; 21:502-508. [DOI: 10.1080/13697137.2018.1495705] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Dama
- Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada
| | - J. L. Mahoney
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
| | - R. J. Van Lieshout
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - B. N. Frey
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - M. Steiner
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
- Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
20
|
Dewart C, Serpico J, Steiner M, Gallo M. Electronic interventions for changing knowledge, attitudes or practice regarding contraception: a systematic review. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Abstract
SummaryThe effect of vitamin E administration on platelet function was evaluated in a group of normal, healthy volunteers. Platelet aggregation induced by collagen, ADP and epinephrine and platelet adhesion to collagen were measured at weekly intervals in 20 men and 27 women divided into 3 experimental groups of 12 individuals each and one control group of 5 men and 6 women. One experimental group was on a 6-week regimen of vitamin E in increasing dosages (4001.U.-1.2001.U.), the second group received aspirin, 300 mg every other day, and the third group was on a combination of vitamin E and aspirin. In the control group, platelet function was measured at weekly intervals. In women, vitamin E by itself produced a small but significant reduction of collagen-induced platelet aggregation. A similar trend was seen in men. However, the reduction never reached statistical significance. Adhesiveness to collagen was not affected by aspirin ingestion but showed a highly significant reduction in vitamin E and vitamin E + aspirin treated individuals. These results suggest that vitamin E administration could have a beneficial effect in patients suffering from arterial thromboembolic diseases.
Collapse
Affiliation(s)
- M Steiner
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, and Brown University Providence, Rl, U.S.A
| |
Collapse
|
22
|
Abstract
SummaryPools of polymerized and total tubulin were measured in human platelets as a function of free sulfhydryl groups both in acid-soluble and acid-precipitable cell fractions. Changes in free thiols were produced either by storage of platelets at room temperature or by addition of the potent oxidizing agent diazene dicarboxylic acid (diamide) and were correlated with shifts in the dynamic equilibrium between assembled and disassembled microtubules and platelet aggregation. Diamide at concentrations of 0.5 to 5 mM depleted acid soluble SH groups and reduced protein thiols while causing a progressive decrease in polymerized tubulin. Similar changes, although not as severe, were initiated by storage of platelets at room temperature. Platelet aggregation especially that induced by collagen showed a positive correlation with the pool of polymerized tubulin. Our results indicate that the state of oxidation of sulfhydryl groups especially in the acid- precipitable fraction plays an important role in determining the position of equilibrium between polymerized and depolymerized tubulin.
Collapse
Affiliation(s)
- M Steiner
- The Division of Hematology/Oncology, The Memorial Hospital, Pawtucket, and Brown University, Providence, RI, USA
| |
Collapse
|
23
|
Abstract
SummaryEstrogens in high doses have been shown to inhibit, in vitro, the thrombin-neutralizing action of antithrombin III (AT III). In this study we investigate the effect of estrogens on AT III in greater detail. To increase the sensitivity of measurement of AT III activity in the absence of heparin, we have developed an assay system utilizing human platelets, AT III and thrombin. The two proteins derived from human plasma were prepared in high purity. Platelet aggregation was induced by approximately 0.02 NIH U of thrombin. AT III was added in amounts that suppressed 95% of the aggregation-inducing effect of thrombin. Estrogens blocked the thrombin-neutralizing effect of AT III in dose-dependent manner. This effect was shown to be specific for AT III. Neither aggregability of platelets nor aggregating effect of thrombin were affected by the steroid hormone. Evidence for binding of estrogen to AT III was obtained from changes in intrinsic fluorescence of AT III. Activity of AT III was also reduced in increasing order of effectiveness by cholesterol, cortisone, testosterone and progesterone. Our studies suggest a direct effect of estrogens and other steroids on AT III, altering its specific neutralization of thrombin.
Collapse
Affiliation(s)
- H Nagasawa
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - B K Kim
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - M Steiner
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - M G Baldini
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| |
Collapse
|
24
|
Abstract
SummaryThe function of nonimmune IgG associated with platelets is unknown. In a series of experiments we have investigated this problem, relating amount of platelet-associated IgG (PAIgG) to platelet volume, serotonin release, adherence of platelets to monocytes and platelet senescence. Most of these studies were performed with human platelets. Platelets freed of preexisting PAIgG by incubation at 22° C were incubated with IgG in a series of concentrations ranging from 0.4 — 27.0 X10-6 M. The IgG preparations used were demonstrably free of aggregated forms of the protein. The amount of PAIgG bound to platelets was determined by the use of fluorescein isothiocyanate-conjugated anti-IgG antibody (F-anti-IgG antibody) which was quantified in a fluorospectrophotometer. Newly bound IgG was assayed similarly by the use of F-IgG. A dose-dependent increase in platelet volume was associated with the binding of nonimmune IgG by platelets. The process which leveled off at an IgG concentration of 1.2 —1.5 X10-5 M was almost fully reversible and was not due to platelet shape change or aggregation. Release of serotonin from IgG-treated platelets was relatively small but to the extent that it occurred was positively related to the IgG concentration to which platelets were exposed. Adherence to autologous monocytes studied quantitatively by the use of formaldehyde-fixed cells was also positively related to the amount of IgG on the platelets. Normal or IgG-defident serum had a potent inhibitory (noncompetitive) action on the binding of F-IgG and F-anti-human IgG antibody to human platelets. Cohorts of platelets prepared in rabbits during the recovery phase of immunological thrombocytopenia induced by injection of heterologous antiserum, showed an age-dependent increase of PAIgG and of IgG binding. These results suggest that PAIgG plays a role in the clearance of senescent platelets.
Collapse
Affiliation(s)
- K Sugiura
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| | - M Steiner
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| | - M Baldini
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| |
Collapse
|
25
|
Abstract
SummaryThe effect of thrombin on the phosphorylating activity of platelet membranes was compared to that of trypsin. Preincubation of non-32P phosphorylated platelet membranes with or without either of these two enzymes resulted in a considerable loss of membrane protein kinase activity which was most severe when trypsin was used. Protein kinase activity and endogenous protein acceptors decreased in parallel. 32P-phosphorylated membranes showed a slow but progressive loss of label which was accelerated by trypsin. Thrombin under these conditions prevented the loss of 32P-phosphate. These results are interpreted to indicate a thrombin-induced destruction of a phosphoprotein phosphatase. The protein kinase activity of phosphorylated platelet membranes using endogenous or exogenous protein substrates showed a significant reduction compared to non-phosphorylated membranes suggesting a deactivation of protein kinase by phosphorylation of platelet membranes. Neither thrombin nor trypsin caused a qualitative change in the membrane polypeptides accepting 32P-phosphate but resulted in quantitative alterations of their ability to become phosphorylated.
Collapse
|
26
|
Sehmbi M, Rowley CD, Minuzzi L, Kapczinski F, Steiner M, Sassi RB, Bock NA, Frey BN. Association of intracortical myelin and cognitive function in bipolar I disorder. Acta Psychiatr Scand 2018. [PMID: 29536533 DOI: 10.1111/acps.12875] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVE Although cognitive dysfunction persists through affective and euthymic states in bipolar disorder (BD), its neurobiological correlates remain undetermined. We explore whole-cortex intracortical myelin (ICM) and cognition in BD-I and controls. METHODS T1 -weighted images (3T) optimized for ICM measurement were analyzed using a surface-based approach. MRI signal was sampled at cortical mid-depth. Cognitive performance was measured via standardized computerized battery and paper-and-pencil Trails B. RESULTS ICM was associated with verbal memory (VM) in BD throughout a cortical network identified with pertinence to VM function, with strongest effects in left caudal middle temporal cortex and left dorsolateral prefrontal cortex (Pcorrected < 0.05). Subanalyses revealed specific association with correct word recognition, without delay. Processing speed, executive function, and reaction time were also predicted by ICM in BD, but not controls, although this did not survive Bonferroni correction. CONCLUSION This is the first study to show VM association with ICM in BD. ICM has been implicated in the integrity of neural connections and neural synchrony. VM dysfunction is one of the most replicated cognitive abnormalities in BD. Therefore, these results provide a novel mechanism for understanding cognitive dysfunction in BD, which can aid in the development of targeted therapeutics to improve cognitive outcomes in BD.
Collapse
Affiliation(s)
- M Sehmbi
- MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
| | - C D Rowley
- MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
| | - L Minuzzi
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - F Kapczinski
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - M Steiner
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - R B Sassi
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - N A Bock
- Department of Psychology, Neuroscience, and Behaviour, McMaster University, Hamilton, ON, Canada
| | - B N Frey
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| |
Collapse
|
27
|
Gaillard S, Gay LM, Steiner M, Andreano K, Davidson BA, Havrilesky LJ, Secord AA, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.5590] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - Brittany Anne Davidson
- Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
| | - Laura Jean Havrilesky
- Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Bhopal R, Gruer L, Cézard G, Douglas A, Steiner M, Millard A, Buchanan D, Katikireddi V, Sheikh A. 1.1-O5Mortality, ethnicity and country of birth on a national scale 2001-2013: the Scottish Health and Ethnicity Linkage Study. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky047.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Bhopal
- The University of Edinburgh, United Kingdom
| | - L Gruer
- The University of Edinburgh, United Kingdom
| | - G Cézard
- The University of Edinburgh, United Kingdom
| | - A Douglas
- The University of Edinburgh, United Kingdom
| | - M Steiner
- The University of Aberdeen, United Kingdom
| | - A Millard
- NHS Health Scotland, Edinburgh, United Kingdom
| | - D Buchanan
- Information Services Division, Edinburgh, United Kingdom
| | - V Katikireddi
- MRC Social and Public Sciences Unit, Glasgow, United Kingdom
| | - A Sheikh
- The University of Edinburgh, United Kingdom
| |
Collapse
|
29
|
Gruer L, Millard A, Williams L, Bhopal R, Katikireddi S, Cezard G, Buchanan D, Douglas A, Steiner M, Sheikh A. 3.10-P23All-cause hospitalisation of different ethnic groups: a data linkage cohort study of 4.62 million people in Scotland. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky048.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- L Gruer
- University of Edinburgh, United Kingdom
| | | | | | - R Bhopal
- University of Edinburgh, United Kingdom
| | | | - G Cezard
- University of Edinburgh, United Kingdom
| | - D Buchanan
- Information Services Division, United Kingdom
| | - A Douglas
- University of Edinburgh, United Kingdom
| | - M Steiner
- University of Aberdeen, United Kingdom
| | - A Sheikh
- University of Edinburgh, United Kingdom
| |
Collapse
|
30
|
Katikireddi S, Cezard G, Bhopal R, Williams L, Douglas A, Millard A, Steiner M, Buchanan D, Sheikh A, Gruer L. 4.1-O1Assessing ethnic equity of health policy by studying avoidable mortality, hospitalisations and unplanned readmissions in linked Scottish data. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky047.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Katikireddi
- MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, United Kingdom
| | - G Cezard
- Department of Geography and Sustainable Development (DGSD), Irvine Building, University of St Andrews, Edinburgh, United Kingdom
| | - R Bhopal
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - L Williams
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - A Douglas
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | | | - M Steiner
- Environmental & Occupational Medicine, Section of Population Health, University of Aberdeen, United Kingdom
| | - D Buchanan
- Information Services Division (ISD), NHS National Services Scotland, United Kingdom
| | - A Sheikh
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - L Gruer
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| |
Collapse
|
31
|
Goldberg H, Stein ME, Steiner M, Sprecher E, Beck D, Kuten A. Consolidation Radiation Therapy following Cytoreductive Surgery, Chemotherapy and Second-Look Laparotomy for Epithelial Ovarian Carcinoma: Long-Term Follow-Up. Tumori 2018; 87:248-51. [PMID: 11695352 DOI: 10.1177/030089160108700407] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background From 1979-1987, 139 stage IC-IV ovarian cancer patients who had undergone cytoreductive surgery received 6-11 cycles of cisplatin and adriamycin. Study design Eighty-four clinically complete responders underwent second-look laparotomy, and 60 of them received consolidation abdominal irradiation. The patients were then followed for a median follow-up of 39 months. Results Five- and 10-year actuarial survival for all patients was 43% and 24%, for no residuum at primary surgery, 80% and 35%, for residual tumor <2 cm, 45% and 35%, and for residual tumor >2 cm, 20% and 4%. Median survival for stage III-IV patients negative at second-look laparotomy was 72 months in irradiated compared to 25 months in non-irradiated patients (P = 0.14) and 77 months in irradiated patients with microscopic disease at second-look laparotomy. Median survival in patients with macroscopic disease at second-look laparotomy was 23.5 months if irradiated compared to 18 months if not (P = 0.05). Conclusions Consolidation whole abdominal irradiation in advanced stages of ovarian cancer may be of value in patients with negative or microscopic disease at second-look laparotomy. Unfortunately, despite the initial survival advantage observed in irradiated patients, owing to late recurrences there was no significant difference in their long-term survival probability.
Collapse
Affiliation(s)
- H Goldberg
- Department of Oncology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
| | | | | | | | | | | |
Collapse
|
32
|
Stemmer SM, Rizel S, Steiner M, Geffen DB, Soussan-Gutman L, Bareket-Samish A, McCullough D, Svedman C, Nisenbaum B, Ryvo L, Peretz T, Fried G, Rosengarten O, Liebermann N, Ben Baruch N. Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In Israel, the RS assay has been reimbursed by Clalit Health Services (CHS, the largest HMO in Israel) since 2006, and the assay is widely used in eligible estrogen receptor (ER)+ patients. Notably, ER+ breast cancer patients have a protracted risk of recurrence with approximately half of all distant recurrences occurring after 5 years from diagnosis. The goal of the current ongoing analysis was to investigate early (≤5 years) and late (>5 years) distant recurrence in N0/N1mi ER+ HER2-negative breast cancer patients who were RS-tested through CHS.
Methods: This analysis of the CHS registry included breast cancer patients with ER+ HER2-negative N0/N1mi disease who underwent RS testing from 1/2006 (CHS approval of the assay) through 1/2009. Data sources included CHS claims arms (for patient/tumor characteristics), Teva Pharmaceuticals (for tumor characteristics, RS result), and medical records (for treatment/recurrence/survival). The study was approved by the institutional review boards of the CHS Community Division and was granted a waiver for obtaining patient consent.
Results: The analysis included 1026 patients with median (interquartile range) follow up of 9.3 (8.8-10.2) years. Most patients were females (99%). Median (range) age was 59 (25-84) years; 92% had N0 and 8% had N1mi disease; 14%, 52%, and 16% had grade 1, 2, and 3 tumors, respectively (grade information was not available for 18% of patients); median (range) tumor size was 1.5 (0.3-6.5) cm. The majority of patients (78%) had invasive ductal carcinoma and 12% had invasive lobular carcinoma. Overall, 489 patients (48%) had RS<18, 434 (42%) had RS 18-30, and 103 (10%) had RS≥31. The use of adjuvant CT was consistent with the RS result: 3%, 27%, and 90% of RS<18, RS 18-30, and RS≥31 patients, respectively. Overall, 25 distant recurrences were reported within 5 years of RS testing: 5 (1.0%) in RS<18 patients, 9 (2.1%) in RS 18-30 patients, and 11 (10.6%) in RS≥31 patients. In the first 5 years, breast cancer-specific death was reported in 8 patients including 3 (0.7%) with RS 18-30 and 5 (4.9%) with RS≥31 results. Among N0 patients with RS 11-25 who did not receive adjuvant CT (n = 540), 5 (0.9%) distant recurrences and one (0.2%) breast cancer death were reported within 5 years of RS testing. Analysis of 'late' recurrences and breast cancer-specific death (from 5 to 9.3 years of follow-up) is ongoing.
Conclusions: These will be the first late recurrence data from over 1000 patients for whom the RS result was used in real-life clinical decision making. Consistent with previous analyses of the CHS registry, CT use was appropriately based on the RS result, and the recurrence/survival outcomes (for the first 5 years) demonstrated the prognostic performance of the RS. Distant recurrence and breast cancer death data beyond 5 years will be presented at the meeting.
Citation Format: Stemmer SM, Rizel S, Steiner M, Geffen DB, Soussan-Gutman L, Bareket-Samish A, McCullough D, Svedman C, Nisenbaum B, Ryvo L, Peretz T, Fried G, Rosengarten O, Liebermann N, Ben Baruch N. Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-14.
Collapse
Affiliation(s)
- SM Stemmer
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - S Rizel
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - M Steiner
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - DB Geffen
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - L Soussan-Gutman
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - A Bareket-Samish
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - D McCullough
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - C Svedman
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - B Nisenbaum
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - L Ryvo
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - T Peretz
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - G Fried
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - O Rosengarten
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - N Liebermann
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - N Ben Baruch
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| |
Collapse
|
33
|
Wolf M, Twaroch TE, Huber S, Reithofer M, Steiner M, Aglas L, Hauser M, Aloisi I, Asam C, Hofer H, Parigiani MA, Ebner C, Bohle B, Briza P, Neubauer A, Stolz F, Jahn-Schmid B, Wallner M, Ferreira F. Amb a 1 isoforms: Unequal siblings with distinct immunological features. Allergy 2017; 72:1874-1882. [PMID: 28464293 PMCID: PMC5700413 DOI: 10.1111/all.13196] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/25/2017] [Indexed: 12/24/2022]
Abstract
Background Ragweed pollen represents a major allergy risk factor. Ragweed extracts contain five different isoforms of the major allergen Amb a 1. However, the immunological characteristics of Amb a 1 isoforms are not fully investigated. Here, we compared the physicochemical and immunological properties of three most important Amb a 1 isoforms. Methods After purification, the isoforms were physicochemically characterized, tested for antibody binding and induction of human T‐cell proliferative responses. Their immunological properties were further evaluated in vitro and in vivo in a mouse model. Results Amb a 1 isoforms exhibited distinct patterns of IgE binding and immunogenicity. Compared to Amb a 1.02 or 03 isoforms, Amb a 1.01 showed higher IgE‐binding activity. Isoforms 01 and 03 were the most potent stimulators of patients’ T cells. In a mouse model of immunization, Amb a 1.01 induced higher levels of IgG and IgE antibodies when compared to isoforms 02 and 03. Interestingly, ragweed‐sensitized patients also displayed an IgG response to Amb a 1 isoforms. However, unlike therapy‐induced antibodies, sensitization‐induced IgG did not show IgE‐blocking activity. Conclusion The present study showed that naturally occurring isoforms of Amb a 1 possess different immunogenic and sensitizing properties. These findings should be considered when selecting sequences for molecule‐based diagnosis and therapy for ragweed allergy. Due to its high IgE‐binding activity, isoform Amb a 1.01 should be included in diagnostic tests. In contrast, due to their limited B‐ and T‐cell cross‐reactivity patterns, a combination of different isoforms might be a more attractive strategy for ragweed immunotherapy.
Collapse
Affiliation(s)
- M. Wolf
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | | | - S. Huber
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. Reithofer
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Steiner
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
- Laboratory for Immunological and
Molecular Cancer Research; Paracelsus Medical University; Salzburg Austria
| | - L. Aglas
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. Hauser
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - I. Aloisi
- Department of Biological, Geological, and Environmental Sciences; University of Bologna; Bologna Italy
| | - C. Asam
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - H. Hofer
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. A. Parigiani
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - C. Ebner
- Allergy Clinic Reumannplatz; Vienna Austria
| | - B. Bohle
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - P. Briza
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - A. Neubauer
- Biomay AG; Vienna Competence Center; Vienna Austria
| | - F. Stolz
- Biomay AG; Vienna Competence Center; Vienna Austria
| | - B. Jahn-Schmid
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Wallner
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - F. Ferreira
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| |
Collapse
|
34
|
Lyons R, Turner SL, Walters AM, Kisser R, Rogmans W, Larsen B, Valkenberg H, Bejko D, Bauer R, Steiner M, Ellsaesser G. Identifying injury related inequalities using data from the European Injury Data Base (IDB). Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- R Lyons
- Swansea University, Swansea, UK
| | | | | | | | | | - B Larsen
- National Institute of Public Health, Odense, Denmark
| | - H Valkenberg
- Consumer Safety Institute, Amsterdam, Netherlands
| | - D Bejko
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - R Bauer
- Austrian Road Safety Board, Vienna, Austria
| | - M Steiner
- Austrian Road Safety Board, Vienna, Austria
| | - G Ellsaesser
- State Office of Occupational Safety, Consumer Protection and Health, Brandenburg, Germany
| |
Collapse
|
35
|
Turner SL, Walters AM, Kisser R, Rogmans W, Larsen B, Valkenberg H, Bejko D, Bauer R, Steiner M, Ellsaesser G, Lyons R. Measuring the burden of injury across Europe. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | - B Larsen
- National Institute of Public Health, Odense, Denmark
| | - H Valkenberg
- Consumer Safety Institute, Amsterdam, Netherlands
| | - D Bejko
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - R Bauer
- Austrian Road Safety Board, Vienna, Austria
| | - M Steiner
- Austrian Road Safety Board, Vienna, Austria
| | - G Ellsaesser
- State Office of Occupational Safety, Consumer Protection and Health, Brandenburg, Germany
| | - R Lyons
- Swansea University, Swansea, UK
| |
Collapse
|
36
|
Diener A, Hartmann P, Urso L, Vives I Batlle J, Gonze MA, Calmon P, Steiner M. Approaches to modelling radioactive contaminations in forests - Overview and guidance. J Environ Radioact 2017; 178-179:203-211. [PMID: 28892730 DOI: 10.1016/j.jenvrad.2017.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 09/01/2017] [Accepted: 09/02/2017] [Indexed: 06/07/2023]
Abstract
Modelling the radionuclide cycle in forests is important in case of contamination due to acute or chronic releases to the atmosphere and from underground waste repositories. This article describes the most important aspects to consider in forest model development. It intends to give an overview of the modelling approaches available and to provide guidance on how to address the quantification of radionuclide transport in forests. Furthermore, the most important gaps in modelling the radionuclide cycle in forests are discussed and suggestions are presented to address the variability of forest sites.
Collapse
Affiliation(s)
- A Diener
- Bundesamt für Strahlenschutz (BfS), Ingolstaedter Landstr. 1, 85764 Oberschleissheim, Germany.
| | - P Hartmann
- Bundesamt für Strahlenschutz (BfS), Ingolstaedter Landstr. 1, 85764 Oberschleissheim, Germany
| | - L Urso
- Bundesamt für Strahlenschutz (BfS), Ingolstaedter Landstr. 1, 85764 Oberschleissheim, Germany
| | | | - M A Gonze
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), France
| | - P Calmon
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), France
| | - M Steiner
- Bundesamt für Strahlenschutz (BfS), Ingolstaedter Landstr. 1, 85764 Oberschleissheim, Germany
| |
Collapse
|
37
|
Bauer R, Steiner M, Kühnelt-Leddhin A, Lyons R, Turner S, Walters W, Larsen B, Valkenberg H, Bejko D, Ellsaesser G, Rogmans W, Kisser R. Scope and patterns of under-reporting of vulnerable road users in official road accident statistics. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.653] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- R Bauer
- Austrian Road Safety Board (KFV), Vienna, Austria
| | - M Steiner
- Austrian Road Safety Board (KFV), Vienna, Austria
| | | | - R Lyons
- Public Health Wales NHS Trust, Swansea, UK
| | - S Turner
- Public Health Wales NHS Trust, Swansea, UK
| | - W Walters
- Public Health Wales NHS Trust, Swansea, UK
| | - B Larsen
- National Institute of Public Health, Copenhagen, Denmark
| | - H Valkenberg
- Consumer Safety Institute, Amsterdam, Netherlands
| | - D Bejko
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - G Ellsaesser
- State Office of Occupational Safety, Consumer Protection and Health, Brandenburg, Potsdam, Germany
| | | | | |
Collapse
|
38
|
Gampenrieder S, Rinnerthaler G, Hackl H, Steiner M, Monzo Fuentes C, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Hainzl S, Peking P, Kocher T, Murauer E, Larcher F, Duarte B, Steiner M, Bauer J, Reichelt J, Koller U. 535 Ex vivo COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Pennestri M, Laganiere C, Bouvette-Turcot A, Steiner M, Meaney M, Gaudreau H. 0038 IS EARLY SLEEP CONSOLIDATION ASSOCIATED WITH DEVELOPMENTAL OUTCOMES? Sleep 2017. [DOI: 10.1093/sleepj/zsx050.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Savoy C, Van Lieshout RJ, Steiner M. Is plasminogen activator inhibitor-1 a physiological bottleneck bridging major depressive disorder and cardiovascular disease? Acta Physiol (Oxf) 2017; 219:715-727. [PMID: 27246986 DOI: 10.1111/apha.12726] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Revised: 04/29/2016] [Accepted: 05/30/2016] [Indexed: 12/16/2022]
Abstract
Major depressive disorder (MDD) is estimated to affect one in twenty people worldwide. MDD is highly comorbid with cardiovascular disease (CVD), itself one of the single largest causes of mortality worldwide. A number of pathological changes observed in MDD are believed to contribute to the development of cardiovascular disease, although no single mechanism has been identified. There are also no biological markers capable of predicting the future risk of developing heart disease in depressed individuals. Plasminogen activator inhibitor-1 (PAI-1) is a prothrombotic plasma protein secreted by endothelial tissue and has long been implicated in CVD. An expanding body of literature has recently implicated it in the pathogenesis of major depressive disorder as well. In this study, we review candidate pathways implicating MDD in CVD and consider how PAI-1 might act as a mediator by which MDD induces CVD development: chiefly through sleep disruption, adiposity, brain-derived neurotrophic factor (BDNF) metabolism, systemic inflammation and hypothalamic-pituitary-adrenal (HPA)-axis dysregulation. As both MDD and CVD are more prevalent in women than in men, and incidence of either condition is dramatically increased during reproductive milestones, we also explore hormonal and sex-specific associations between MDD, PAI-1 and CVD. Of special interest is the role PAI-1 plays in perinatal depression and in cardiovascular complications of pregnancy. Finally, we propose a theoretical model whereby PAI-1 might serve as a useful biomarker for CVD risk in those with depression, and as a potential target for future treatments.
Collapse
Affiliation(s)
- C. Savoy
- Women's Health Concerns Clinic; St. Joseph's Healthcare; Department of Psychiatry and Behavioural Neurosciences; McMaster University; Hamilton ON Canada
- McMaster Integrated Neuroscience Discovery and Study Program; McMaster University; Hamilton ON Canada
| | - R. J. Van Lieshout
- Women's Health Concerns Clinic; St. Joseph's Healthcare; Department of Psychiatry and Behavioural Neurosciences; McMaster University; Hamilton ON Canada
- McMaster Integrated Neuroscience Discovery and Study Program; McMaster University; Hamilton ON Canada
| | - M. Steiner
- Women's Health Concerns Clinic; St. Joseph's Healthcare; Department of Psychiatry and Behavioural Neurosciences; McMaster University; Hamilton ON Canada
- McMaster Integrated Neuroscience Discovery and Study Program; McMaster University; Hamilton ON Canada
| |
Collapse
|
42
|
Unternaehrer E, Greenlaw K, Hari Dass S, Chen L, Bouvette-Turcot A, Cost K, O’Donnell K, Gaudreau H, McEwen L, MacIsaac J, Kobor M, Fleming A, Atkinson L, Lydon J, Steiner M, Ciampi A, Greenwood C, Meaney M. Intergenerational Transmission of Well Being–Genetic and Epigenetic Mechanisms. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionMaternal mental well being influences offspring development. Research suggests that an interplay between genetic and environmental factors underlies this familial transmission of mental disorders.ObjectivesTo explore an interaction between genetic and environmental factors to predict trajectories of maternal mental well being, and to examine whether these trajectories are associated with epigenetic modifications in mothers and their offspring.MethodWe assessed maternal childhood trauma and rearing experiences, prenatal and postnatal symptoms of depression and stress experience from 6 to 72 months postpartum, and genetic and epigenetic variation in a longitudinal birth-cohort study (n = 262) (Maternal adversity, vulnerability and neurodevelopment project). We used latent class modeling to describe trajectories in maternal depressive symptoms, parenting stress, marital stress and general stress, taking polygenetic risk for major depressive disorder (MDD), a composite score for maternal early life adversities, and prenatal depressive symptoms into account.ResultsGenetic risk for MDD associated with trajectories of maternal well being in the postpartum, conditional on the experience of early life adversities and prenatal symptoms of depression. We will explore whether these trajectories are also linked to DNA methylation patterns in mothers and their offspring. Preliminary analyses suggest that maternal early life adversities associate with offspring DNA methylation age estimates, which is mediated through maternal mental well being and maternal DNA methylation age estimates.ConclusionWe found relevant gene-environment interactions associated with trajectories of maternal well being. Our findings inform research on mechanisms underlying familial transmission of vulnerability for psychopathology and might thus be relevant to prevention and early intervention programs.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
43
|
Stemmer S, Steiner M, Rizel S, Geffen D, Nisenbaum B, Peretz T, Isaacs K, Rosengarten O, Fried G, Svedman C, Ben-Baruch N. Clinical outcomes following Recurrence Score-based therapy in N+ ER+ breast cancer: a cohort study. Breast 2017. [DOI: 10.1016/s0960-9776(17)30337-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
44
|
Trethewey R, Esliger D, Petherick E, Evans R, Greening N, James B, Kingsnorth A, Morgan M, Orme M, Singh S, Sherar L, Toms N, Steiner M. P47 The influence of muscle mass in the assessment of lower limb strength in copd. Thorax 2016. [DOI: 10.1136/thoraxjnl-2016-209333.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Lyons RA, Turner S, Rogmans W, Kisser R, Larsen B, Valkenberg H, Bejko D, Bauer R, Steiner M. The European injury data base: supporting injury research and policy across Europe. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw168.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Tombeau Cost K, Unternaehrer E, Plamondon A, Steiner M, Meaney M, Atkinson L, Kennedy JL, Fleming AS. Thinking and doing: the effects of dopamine and oxytocin genes and executive function on mothering behaviours. Genes Brain Behav 2016; 16:285-295. [PMID: 27620964 DOI: 10.1111/gbb.12337] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 08/11/2016] [Accepted: 09/08/2016] [Indexed: 11/28/2022]
Abstract
Animal and human studies suggest that initial expression of maternal behaviour depends on oxytocin and dopamine systems. However, the mechanism by which these systems affect parenting behaviours and the timing of these effects are not well understood. This article explores the role of mothers' executive function in mediating the relation between oxytocin and dopamine gene variants and maternal responsiveness at 48 months post-partum. Participants (n = 157) were mothers recruited in the Maternal Adversity, Vulnerability and Neurodevelopment Study, which assesses longitudinally two cohorts of mothers and children in Canada. We examined single nucleotide polymorphisms (SNPs) related to the dopamine and oxytocin systems (DRD1 rs686, DRD1 rs265976, OXTR rs237885 and OXTR rs2254298), assessed mothers' decision-making at 48 months using the Cambridge Neurological Automated Testing Battery (CANTAB) and evaluated maternal responsiveness from videotaped interactions during the Etch-A-Sketch co-operation task. Mediation analyses showed that OXTR rs2254298 A-carriers had an indirect effect on positive parenting which was mediated by mothers' performance on decision-making task (estimate = 0.115, P < 0.005), while OXTR rs2254298 A-carriers had both direct and indirect effects on physically controlling parenting, also mediated through enhanced performance on decision-making (estimate = -0.059, P < 0.005). Dopamine SNPs were not associated with any measure of executive function or parenting (all P > 0.05). While oxytocin has previously been associated with only the early onset of maternal behaviour, we show that an OXTR polymorphism is involved in maternal behaviour at 48 months post-partum through mothers' executive function. This research highlights the importance of the oxytocin system to maternal parenting beyond infancy.
Collapse
Affiliation(s)
- K Tombeau Cost
- Department of Psychology, University of Toronto Mississauga, Mississauga.,Fraser Mustard Institute for Human Development, Toronto
| | - E Unternaehrer
- Ludmer Centre for Neuroinformatics & Mental Health.,Douglas Mental Health University, Institute of McGill University, Montreal
| | - A Plamondon
- Department of Educational Fundamentals and Practices, Laval University, Quebec
| | - M Steiner
- Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton
| | - M Meaney
- Ludmer Centre for Neuroinformatics & Mental Health.,Douglas Mental Health University, Institute of McGill University, Montreal.,Sackler Program for Epigenetics & Psychobiology at McGill University, Montreal, Canada.,Singapore Institute for Clinical Sciences, Singapore
| | - L Atkinson
- Department of Psychology, Ryerson University
| | - J L Kennedy
- Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
| | - A S Fleming
- Department of Psychology, University of Toronto Mississauga, Mississauga.,Fraser Mustard Institute for Human Development, Toronto
| | | |
Collapse
|
47
|
Stemmer S, Steiner M, Rizel S, Geffen D, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, Svedman C, Shak S, Liebermann N, Ben-Baruch N. First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Hainzl S, Kocher T, Murauer E, Larcher F, Steiner M, Bauer J, Reichelt J, Koller U. 164 CRISPR/Cas9-mediated gene repair in the COL7A1 gene. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Fischbacher CM, Steiner M, Bhopal R, Chalmers J, Jamieson J, Knowles D, Povey C. Variations in all Cause and Cardiovascular Mortality by Country of Birth in Scotland, 1997-2003. Scott Med J 2016; 52:5-10. [PMID: 18092629 DOI: 10.1258/rsmsmj.52.4.5] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background and Aims Country of birth provides a proxy for ethnic group for recent migrants. Major differences in mortality by country of birth have been demonstrated in England and Wales, but similar published data for Scotland are lacking. We aimed to examine variations in mortality by country of birth for Scottish residents. Methods We calculated standardised mortality ratios by country of birth for Scottish residents aged 25 years and over between January 1997 and March 2003. Results and Conclusion Comparisons with England and Wales showed high allcause, coronary heart disease (CHD) and stroke mortality among Scottish residents born in Scotland, Northern Ireland, the Republic of Ireland, India and Hong Kong. However, most country of birth groups had similar or lower mortality than the Scottish born. These are the first data on mortality by country of birth in Scotland and they demonstrate major variations. Comparisons within the Scottish population might be interpreted as reassuring, since they do not show the excesses in CHD mortality by country of birth reported in England and Wales. However, the use of England and Wales as a comparison group shows a substantial excess of CHD risk among South Asians in Scotland, comparable to that reported in England and Wales.
Collapse
Affiliation(s)
- CM Fischbacher
- Consultant in Public Health Medicine, Information Services Division, NHS National Services Gyle Square, 1 South Gyle Crescent, Edinburgh, EH 12 9EB
- Honorary Senior Lecturer, Department of Public Health Sciences, University of Edinburgh, EH8 9AG
| | - M Steiner
- Senior Registrar, Department of Environmental and Occupational Medicine, Liberty Safe Work Research Centre, Forresterhill Road, Aberdeen, AB25 2ZP. (Formerly, Department of Public Health Sciences, University of Edinburgh, EH8 9AG)
| | - R Bhopal
- Professor of Public Health, Department of Public Health Sciences, University of Edinburgh, EH8 9AG
| | - J Chalmers
- Consultant in Public Health Medicine, Information Services Division, NHS National Services Gyle Square, 1 South Gyle Crescent, Edinburgh, EH 12 9EB
- Honorary Senior Lecturer, Department of Public Health Sciences, University of Edinburgh, EH8 9AG
| | - J Jamieson
- Programme Manager, Information Services Division, NHS National Services Gyle Square, 1 South Gyle Crescent, Edinburgh, EH 12 9EB
| | - D Knowles
- Head of Group, Information Services Division, NHS National Services Gyle Square, 1 South Gyle Crescent, Edinburgh, EH 12 9EB
| | - C Povey
- Information Analyst, Information Services Division, NHS National Services Gyle Square, 1 South Gyle Crescent, Edinburgh, EH 12 9EB
| |
Collapse
|
50
|
Abstract
A placebo controlled, double-blind, crossover study of Venostasin retard was carried out in 52 pregnant women with oedema due to venous insufficiency. There was a statistically significant reduction of the oedema in the Venostasin treated group, who also showed greater resistance to oedema provocation. During Venostasin treatment patients also recorded less severe symptoms of pain, fatigue, swelling and itching.
Collapse
Affiliation(s)
- M. Steiner
- Department of Obstetrics and Gynaecology, University of Freiburg, FRG
| | - H. G. Hillemanns
- Department of Obstetrics and Gynaecology, University of Freiburg, FRG
| |
Collapse
|